Maternal Use of Acetaminophen (Paracetamol) During Pregnancy and Neurodevelopmental Disorders in Offspring
The Journal of Clinical Psychiatry · 10.11.2025 · 86 (4)
DOI: 10.4088/jcp.25f16187 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Clinical Psychiatry, online erschienen am 10.11.2025. Verfasst von Chittaranjan Andrade. Beteiligte Einrichtung: Author Affiliations: Department of Clinical Psychopharmacology and Neurotoxicology, National Institute of Mental Health and Neurosciences, Bangalore,…. Hauptthemen laut MEDLINE: Acetaminophen, Prenatal Exposure Delayed Effects, Autism Spectrum Disorder, Analgesics, Non-Narcotic. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
The US Administration has moved to declare gestational exposure to acetaminophen (paracetamol) a risk factor for autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) in children. This article examines the science on the subject. Studies suggest that about half of women use acetaminophen during pregnancy; nevertheless, there is no epidemic of neurodevelopmental disorders (NDDs) in offspring. Two large population-based studies, one Swedish and the other Japanese, found that maternal use of acetaminophen during pregnancy was associated with an increased risk of ASD, ADHD, and intellectual disability (ID) in children. However, the risks were very small in fully adjusted analyses; hazard ratios (HRs) were mostly in the 1.05-1.07 range. Importantly, maternal use of aspirin, other NSAIDs, opioids, or antimigraine drugs during pregnancy was also associated with an increased risk of ASD and ADHD (but not ID). Most importantly, in sibling analyses, gestational exposure to acetaminophen, aspirin, and other analgesic drug categories was not associated with an increased risk of NDDs. There are many key points. Acetaminophen has a safety profile that is better than that of alternative treatments. The magnitude of increase in absolute risk for NDDs is very small (eg, by 0.09% at age 10, for ASD). There are many unmeasured confounds that, evenif weak, could nullify the relationship between acetaminophen and NDDs. Sibling analyses suggest that shared genetic and shared environment risk factors (rather than acetaminophen exposure) may explain the NDD risk. Analyses of other analgesic drug groups suggest that pain and inflammation, rather than drug exposure, may also explain the NDD risk. Finally, for reasons that are explained, making acetaminophen unavailable during pregnancy does not mean that the NDD risk will reduce. These points need to be discussed with women in a shared decision-making process that is both equitable and free from guilting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Author Affiliations: Department of Clinical Psychopharmacology and Neurotoxicology, National Institute of Mental Health and Neurosciences, Bangalore, India; Department of Psychiatry, Kasturba Medical College, Manipal Ac…
- Corresponding Author: Chittaranjan Andrade, MD, Department of Clinical Psychopharmacology and Neurotoxicology, National Institute of Mental Health and Neurosciences, Bangalore 560029, India (andradec@gmail.com).
Zitieren
APA
Andrade, C. (2025). Maternal Use of Acetaminophen (Paracetamol) During Pregnancy and Neurodevelopmental Disorders in Offspring. The Journal of Clinical Psychiatry, 86(4). https://doi.org/10.4088/jcp.25f16187
Vancouver
Andrade C. Maternal Use of Acetaminophen (Paracetamol) During Pregnancy and Neurodevelopmental Disorders in Offspring. The Journal of Clinical Psychiatry. 2025;86(4). doi:10.4088/jcp.25f16187
BibTeX
@article{Andrade2025,
author = {Andrade, Chittaranjan},
title = {Maternal Use of Acetaminophen (Paracetamol) During Pregnancy and Neurodevelopmental Disorders in Offspring},
journal = {The Journal of Clinical Psychiatry},
year = {2025},
volume = {86},
number = {4},
doi = {10.4088/jcp.25f16187}
}
EUVIMED